Trade

JB Chemicals & Pharmaceuticals Ltd share price

Moderate risk
  • 22%Low risk
  • 22%Moderate risk
  • 22%Balanced risk
  • 22%High risk
  • 22%Extreme risk
  • 2,177.80(0.81%)
    May 21, 2026 15:29:00 PM IST
    • NSE
    • BSE
  • Vol : 420.39 K (NSE + BSE)
    Last 20 day avg : 328.23 K

JB Chemicals & Pharmaceuticals Ltd is trading 0.81% upper at Rs 2,177.80 as compared to its last closing price. JB Chemicals & Pharmaceuticals Ltd has been trading in the price range of 2,196.30 & 2,156.00. There are 7 analysts who have initiated coverage on JB Chemicals & Pharmaceuticals Ltd. There are 4 analysts who have given it a strong buy rating & 0.00 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 101.37 Crores in its last quarter.Listed peers of JB Chemicals & Pharmaceuticals Ltd include Sun Pharmaceutical Industries (0.57%), Dr Reddy's Laboratories (-0.22%), Cipla (0.15%).The Mutual Fund holding in JB Chemicals & Pharmaceuticals Ltd was at 19.00% in 31 Mar 2026. The MF holding has decreased from the last quarter. The FII holding in JB Chemicals & Pharmaceuticals Ltd was at 16.33% in 31 Mar 2026. The FII holding has increased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on May 21, 2026, 07:32 PM UTC

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.40
    Low volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.01
    Lower than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.38
    Lower than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    8.37
    Lower than historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    38.91
    Lower than historical values
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -
Price range
Day Range
Lowest
2,156.00
Highest
2,196.30
52 week range
Lowest
1,603.05
Highest
2,224.00
JB Chemicals & Pharmaceuticals Ltd Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Sun Pharmaceutical Industries
Bullish
1,891.150.574,53,739.5436.245.770.920.50
Dr Reddy's Laboratories
Bullish
1,319.00-0.221,10,244.5618.633.140.632.34
Cipla
Moderately Bullish
1,401.650.151,13,101.6322.953.870.870.81
Divi's Laboratories
Bullish
6,856.20-0.541,81,305.6778.6111.520.460.01
Torrent Pharmaceuticals
Bullish
4,474.051.001,50,429.6167.3217.10.8317.62
Mutual Fund Ownership
View all
Kotak Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 15.93
  • % of AUM 3.66
PGIM India Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 3.53
  • % of AUM 3.24
LIC MF Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 2.48
  • % of AUM 2.94
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 23.63
  • % of AUM 2.90
Mirae Asset Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 75.25
  • % of AUM 2.80
JB Chemicals & Pharmaceuticals Ltd Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2026-05-11Audited Results & Final Dividend
2026-02-05Interim Dividend
2026-01-16Quarterly Results
2025-11-11Quarterly Results
2025-07-30Quarterly Results
About the company JB Chemicals & Pharmaceuticals Ltd
  • IndustryBiotechnology & Drugs
  • ISININE572A01036
  • BSE Code506943
  • NSE Code
J.B. Chemicals & Pharmaceuticals Limited is an India-based pharmaceutical company. The Company specializes in gastroenterology, hypertension and dermatology. It is also focused on other therapeutic categories like nephrology, respiratory, virology, diabetes, and nicotine replacement therapy (NRT). The Company is engaged in the business of manufacturing and marketing of a diverse range of pharmaceutical formulations, herbal remedies and active pharmaceutical ingredients (APIs). Its brands include Nicardia, Cilacar, Rantac, Metrogyl, and Cilacar-T. It specializes in manufacturing medicated and herbal lozenges. It produces hard-candy lozenges, soft-center lozenges and powder-filled lozenges for varied medical needs. Its API products include Diclofenac Sodium, Diclofenac Diethylamine, Diclofenac Acid, Nifedipine, and others. It maintains a direct presence in Russia and South Africa, while leveraging distributor partnerships across the United States, Asia, Africa, and Latin America.
  • Management Info
  • Nikhil ChopraChief Executive Officer, Whole Time Director
  • Narayan SarafChief Financial Officer
  • Sandeep PhadnisCompany Secretary, Compliance Officer, Vice President - Secretarial
JB Chemicals & Pharmaceuticals Ltd Share Price FAQs

JB Chemicals & Pharmaceuticals Ltd is trading at 2177.80 as on Thu May 21 2026 09:59:00. This is 0.81% upper as compared to its previous closing price of 2160.35.

The market capitalization of JB Chemicals & Pharmaceuticals Ltd is 34813.39 Cr as on Thu May 21 2026 09:59:00.

The average broker rating on JB Chemicals & Pharmaceuticals Ltd is Buy. The breakup of analyst rating is given below -

  • 4 analysts have given a strong buy rating
  • 0.00 analysts have given a buy rating
  • 3 analysts have given a hold rating
  • 0.00 analysts have given a sell rating
  • 0.00 analysts have given a strong sell rating

The 52 wk high for JB Chemicals & Pharmaceuticals Ltd is 2224.00 whereas the 52 wk low is 1603.05

JB Chemicals & Pharmaceuticals Ltd can be analyzed on the following key metrics -

  • TTM P/E:
  • Sector P/E: -
  • Dividend Yield: %
  • D/E ratio: -

JB Chemicals & Pharmaceuticals Ltd reported a net profit of 709.47 Cr in 2026.

The Mutual Fund Shareholding was 19.00% at the end of 31 Mar 2026.